Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer

The study will investigate the role of cemiplimab in combination with platinum doublet chemotherapy in stage I resectable non-small cell lung cancer (NSCLC). Sub-4cm NSCLC tumors are highly lethal malignancies, yet no therapies are used in these patients to improve chances of survival with surgery alone. Here will be examined the ability of 3 cycles of cemiplimab-chemotherapy to induce pathologic complete responses to treatment.

NCT Number	NCT07720167
Lead Sponsor	Medical University of South Carolina
Conditions	Non-Small Cell Lung Cancer
Enrollment	38 participants
Start Date	2026-11-01
Primary Completion	2029-11-01 (estimated)
Study Completion	2030-11-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-22